Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 13(1): 4590, 2023 Mar 21.
Article in English | MEDLINE | ID: mdl-36944652

ABSTRACT

Seafloor methane emissions can affect Earth's climate and ocean chemistry. Vast quantities of methane formed by microbial decomposition of organic matter are locked within gas hydrate and free gas on continental slopes, particularly in large areas with high sediment accumulations such as deep-sea fans. The release of methane in slope environments has frequently been associated with dissociation of gas hydrates near the edge of the gas hydrate stability zone on the upper slope, with discharges in greater water depths less understood. Here we show, using data from the Rio Grande Cone (western South Atlantic), that the intrinsic, gravity-induced downslope collapse of thick slope sediment accumulations creates structures that serve as pathways for gas migration, unlocking methane and causing seafloor emissions via giant gas flares in the water column. The observed emissions in the study region (up to 310 Mg year-1) are three times greater than estimates for the entire US North Atlantic margin and reveal the importance of collapsing sediment accumulations for ocean carbon cycling. Similar outgassing systems on the Amazon and Niger fans suggest that gravity tectonics on passive margins is a common yet overlooked mechanism driving massive seafloor methane emissions in sediment-laden continental slopes.

2.
Int J Immunopathol Pharmacol ; 18(3): 487-96, 2005.
Article in English | MEDLINE | ID: mdl-16164829

ABSTRACT

We analyzed soluble vascular adhesion molecules (sVCAM-1), reactive oxygen metabolites (ROMs) level, total antioxidant status (TAS) and telediastolic left ventricular volume (TLVV) in patients with myocardial infarction undergoing reperfusion therapy and treated with antioxidant vitamins (AT) or placebo (P) before and for 1 month after reperfusion. After reperfusion, sVCAM-1 serum concentration, reactive oxygen metabolites level, and TLVV were significantly higher in patients treated with placebo than in those treated with antioxidant vitamins, while TAS was significantly higher in patients treated with antioxidant supplementation. We observed that 48 hours after reperfusion sVCAM-1 (P) vs sVCAM-1 (AT) was 2.03+/-0.5 vs 1.63+/-0.7 microg/ml with p < 0.01; ROMs (P) vs ROMs (AT) were 335.60+/-35.80 vs 307.50+/-47.10 U.CARR with p < 0.05; TAS (P) vs TAS (AT) was 526.47+/-44.24 vs 737.65+/-51.15 micromol/l with p < 0.01; 1 week after reperfusion TLVV (P) vs TLVV (AT) was 125.12+/-29.80 vs 119.40+/-29.40 ml with p < 0.05; 1 month after reperfusion TLVV (P) vs TLVV (AV) was 132.00+/-33.50 vs 123.40+/-21.60 ml with p < 0.05. In the first period after infarction, vitamin treatment improves the antioxidant system and reduces oxidative stress, inflammatory process and left ventricular remodeling.


Subject(s)
Antioxidants/therapeutic use , Myocardial Infarction/drug therapy , Oxidative Stress/drug effects , Ventricular Remodeling/drug effects , Vitamins/therapeutic use , Adult , Aged , Aged, 80 and over , Ascorbic Acid/therapeutic use , Drug Therapy, Combination , Enzyme-Linked Immunosorbent Assay , Female , Humans , Lipid Peroxides/analysis , Male , Malondialdehyde/analysis , Middle Aged , Reactive Oxygen Species/analysis , Thiobarbituric Acid Reactive Substances/analysis , Time Factors , Vitamin A/blood , Vitamin A/therapeutic use , Vitamin E/blood , Vitamin E/therapeutic use , Vitamins/blood
3.
Int J Immunopathol Pharmacol ; 17(1): 27-32, 2004.
Article in English | MEDLINE | ID: mdl-15000863

ABSTRACT

Antithrombin-III exerts antiinflammatory effects via ligation of heparan sulfate proteoglycans. Here we show in vitro that recombinant human antithrombin-III attenuates CD11b/CD18 expression of activated neutrophils and monocytes in whole blood ex vivo. As leukocyte integrin expression is triggered by extracorporeal circulation, this observation may be of relevance for pharmacological treatment during cardiopulmonary bypass.


Subject(s)
Antithrombin III/pharmacology , CD18 Antigens/biosynthesis , Leukocytes/drug effects , Leukocytes/metabolism , Adult , CD18 Antigens/metabolism , Humans , Recombinant Proteins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...